arrow
M

Maura N. Dickler

University of Toronto
H指数:58
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advancing Global Health Equity in Oncology Clinical Trial Access
2024-09-240
PRE
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
2023-06-015
OAAI
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
2020-08-151
PRE
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1
2020-08-124
OAAI
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

PTEN和ESR1的改变促进了对alpelisib加芳香酶抑制剂的临床耐药性

2020-03-23104
OAAI
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
2019-08-0117
OAAI
Double PIK3CA mutations in cis enhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer
2019-07-010
PRE
A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients

乳腺癌患者新辅助或每周紫杉醇辅助化疗期间针刺降低化疗引起的周围神经病变严重程度的IIA期试验

2018-09-0178
OAAI
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study
2018-05-224
OAAI
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing

通过肿瘤和正常DNA中癌症相关基因的通用测序与基于指南的种系检测来检测晚期癌症患者的突变

2017-09-05368
OAAI